181 related articles for article (PubMed ID: 30277174)
1. The Application of Pre-clinical Animal Models to Optimise Nanoparticulate Drug Delivery for Hepatocellular Carcinoma.
Zhang Z; Song L; Guo J
Pharm Nanotechnol; 2018; 6(4):221-231. PubMed ID: 30277174
[TBL] [Abstract][Full Text] [Related]
2. New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma.
Turato C; Balasso A; Carloni V; Tiribelli C; Mastrotto F; Mazzocca A; Pontisso P
J Control Release; 2017 Dec; 268():184-197. PubMed ID: 29051062
[TBL] [Abstract][Full Text] [Related]
3. Conventional and hybrid nanoparticulate systems for the treatment of hepatocellular carcinoma: An updated review.
Fawzi Kabil M; Nasr M; El-Sherbiny IM
Eur J Pharm Biopharm; 2021 Oct; 167():9-37. PubMed ID: 34271117
[TBL] [Abstract][Full Text] [Related]
4. Insights into Nanotherapeutic Strategies as an Impending Approach to Liver Cancer Treatment.
Singh A; Shafi S; Upadhyay T; Najmi AK; Kohli K; Pottoo FH
Curr Top Med Chem; 2020; 20(20):1839-1854. PubMed ID: 32579503
[TBL] [Abstract][Full Text] [Related]
5. Glycyrrhetinic Acid Mediated Drug Delivery Carriers for Hepatocellular Carcinoma Therapy.
Cai Y; Xu Y; Chan HF; Fang X; He C; Chen M
Mol Pharm; 2016 Mar; 13(3):699-709. PubMed ID: 26808002
[TBL] [Abstract][Full Text] [Related]
6. Magnetic Nanoparticles for Hepatocellular Carcinoma Diagnosis and Therapy.
Ungureanu BS; Teodorescu CM; Săftoiu A
J Gastrointestin Liver Dis; 2016 Sep; 25(3):375-83. PubMed ID: 27689203
[TBL] [Abstract][Full Text] [Related]
7. Glycyrrhetinic Acid-Mediated Polymeric Drug Delivery Targeting the Acidic Microenvironment of Hepatocellular Carcinoma.
Zhang J; Zhang M; Ji J; Fang X; Pan X; Wang Y; Wu C; Chen M
Pharm Res; 2015 Oct; 32(10):3376-90. PubMed ID: 26148773
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
Varshosaz J; Farzan M
World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
[TBL] [Abstract][Full Text] [Related]
9. Drug delivery system targeting advanced hepatocellular carcinoma: Current and future.
Zhang X; Ng HLH; Lu A; Lin C; Zhou L; Lin G; Zhang Y; Yang Z; Zhang H
Nanomedicine; 2016 May; 12(4):853-869. PubMed ID: 26772424
[TBL] [Abstract][Full Text] [Related]
10. Nanomedicine as a putative approach for active targeting of hepatocellular carcinoma.
Elnaggar MH; Abushouk AI; Hassan AHE; Lamloum HM; Benmelouka A; Moatamed SA; Abd-Elmegeed H; Attia S; Samir A; Amr N; Johar D; Zaky S
Semin Cancer Biol; 2021 Feb; 69():91-99. PubMed ID: 31421265
[TBL] [Abstract][Full Text] [Related]
11. Active radar guides missile to its target: receptor-based targeted treatment of hepatocellular carcinoma by nanoparticulate systems.
Yan JJ; Liao JZ; Lin JS; He XX
Tumour Biol; 2015 Jan; 36(1):55-67. PubMed ID: 25424700
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in hepatocellular carcinoma-targeted nanoparticles.
Liu X; Bai Y; Zhou B; Yao W; Song S; Liu J; Zheng C
Biomed Mater; 2024 May; 19(4):. PubMed ID: 38697209
[TBL] [Abstract][Full Text] [Related]
13. Enhanced immunotherapy of SM5-1 in hepatocellular carcinoma by conjugating with gold nanoparticles and its in vivo bioluminescence tomographic evaluation.
Ma X; Hui H; Jin Y; Dong D; Liang X; Yang X; Tan K; Dai Z; Cheng Z; Tian J
Biomaterials; 2016 May; 87():46-56. PubMed ID: 26897539
[TBL] [Abstract][Full Text] [Related]
14. Lactobionic acid coupled liposomes: an innovative strategy for targeting hepatocellular carcinoma.
Bansal D; Yadav K; Pandey V; Ganeshpurkar A; Agnihotri A; Dubey N
Drug Deliv; 2016; 23(1):140-6. PubMed ID: 24786484
[TBL] [Abstract][Full Text] [Related]
15. Receptor-mediated protection of normal hepatocytes during chemotherapy for hepatocellular carcinoma.
Keegan-Rogers V; Wu CH; Wu GY
Targeted Diagn Ther; 1991; 4():105-25. PubMed ID: 1665717
[No Abstract] [Full Text] [Related]
16. TGF-beta inihibitor-loaded polyelectrolyte multilayers capsules for sustained targeting of hepatocarcinoma cells.
Vergaro V; Baldassarre F; De Santis F; Ciccarella G; Giannelli G; Leporatti S
Curr Pharm Des; 2012; 18(27):4155-64. PubMed ID: 22630086
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Bagi CM; Gebhard DF; Andresen CJ
Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
[TBL] [Abstract][Full Text] [Related]
19. Glycyrrhizin-modified O-carboxymethyl chitosan nanoparticles as drug vehicles targeting hepatocellular carcinoma.
Shi L; Tang C; Yin C
Biomaterials; 2012 Oct; 33(30):7594-604. PubMed ID: 22796165
[TBL] [Abstract][Full Text] [Related]
20. Targeted arsenite-loaded magnetic multifunctional nanoparticles for treatment of hepatocellular carcinoma.
Chi X; Zhang R; Zhao T; Gong X; Wei R; Yin Z; Lin H; Li D; Shan H; Gao J
Nanotechnology; 2019 Apr; 30(17):175101. PubMed ID: 30654348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
